Browse Drug Recalls
62 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 62 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 62 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Apr 14, 2014 | HALOPERIDOL DECANOATE INJECTION, 50 mg/mL, 1 mL vial, Rx only, Fresenius Kabi... | Failed Impurities/Degradation Specifications: Fresenius Kabi is recalling three lots of Haloperid... | Class III | Fresenius Kabi USA LLC |
| Jan 22, 2014 | Heparin Sodium Injection, USP 10,000 USP units per 10 mL (1,000 USP units per... | Subpotent; 18 month time point | Class II | Fresenius Kabi USA, LLC |
| Dec 6, 2013 | FOLIC ACID INJECTION, USP; 5 mg/mL ; For IM, IV or SC Use; 10 mL; Multiple Do... | Failed Impurities/Degradation specifications: out-of-specification results 14 & 15 month time point | Class III | Fresenius Kabi USA, LLC |
| Nov 8, 2013 | PACLITAXEL INJECTION, USP (semisynthetic); 300 mg/50 mL; (6 mg/mL); Multiple ... | Labeling: Incorrect or Missing Package Insert- Missing text on the product insert in the "Clinica... | Class III | Fresenius Kabi USA, LLC |
| Oct 31, 2013 | Tranexamic Acid Injection USP, 1000mg/10mL, 10mL vial, Rx only. Mfd by: Fres... | Presence of Particulate Matter: Particulate matter consistent with delamination of the glass vial... | Class II | Fresenius Kabi USA, LLC |
| Jul 1, 2013 | Benztropine Mesylate Injection, USP, 2 mg/2 mL (1 mg/1 mL), 2 mL Single Dose ... | Presence of particulate matter: characterized as thin colorless flakes that are visually and che... | Class II | Fresenius Kabi USA, LLC |
| Jun 24, 2013 | Oxytocin Injection, USP, (Synthetic), 10 USP Units/mL, for IV Infusion or IM ... | Subpotent Drug; 15-month stability test station | Class II | Fresenius Kabi USA, LLC |
| May 25, 2013 | Magnesium Sulfate Injection, USP, 50% (25 grams/50 mL), For IM or IV Use, 50 ... | Presence of Particulate Matter: Glass particulate matter was observed in a retention sample durin... | Class I | Fresenius Kabi USA, LLC |
| May 21, 2013 | Folic Acid Injection, USP, 5 mg/mL, For IM, IV or SC Use, 10 mL, Multiple Dos... | Failed Impurities/Degradation Specification | Class III | Fresenius Kabi USA, LLC |
| Sep 27, 2012 | ONDANSETRON INJECTION, USP, 4 mg/ 2 mL (2 mg/mL), For IM or IV Use, Single D... | Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles. | Class II | Fresenius Kabi USA, LLC |
| Sep 27, 2012 | MIDAZOLAM HYDROCHLORIDE INJECTION, 5 mg/1 mL, C-IV, For IM or IV Use, 2 mL Vi... | Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles. | Class II | Fresenius Kabi USA, LLC |
| Sep 27, 2012 | CYANOCOBALAMIN INJECTION, USP, 1000 mcg/mL, For IM or IV Use, Multiple Dose 2... | Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles. | Class II | Fresenius Kabi USA, LLC |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.